Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX3232 produced a dramatic 78% reduction in high-sensitivity C‑reactive protein (hsCRP) over 12 weeks as a monotherapy, and rapid biomarker declines within the first week in patients with obesity and cardiovascular risk factors. The company said the drug was safe and well tolerated and also reduced IL‑6, Lp(a), fibrinogen and measures of liver inflammation in subsets. Investors sent Ventyx shares sharply higher on the results, and analysts suggested the data reposition the program toward cardiometabolic and inflammatory indications rather than weight loss. The readout reinforces industry interest in NLRP3 as a therapeutic axis and could accelerate partnering conversations for oral inflammasome inhibitors.